Enhertu (Fam-Trastuzumab Deruxtecan-nxki) in the USA: Cost, Uses & Access Guide

What is Enhertu (Fam-Trastuzumab Deruxtecan-nxki)?

Enhertu (fam-trastuzumab deruxtecan-nxki) is an advanced antibody-drug conjugate (ADC) used to treat certain types of HER2-positive and HER2-low cancers. It combines targeted therapy with chemotherapy to deliver powerful anti-cancer effects directly to tumor cells.

Developed by Daiichi Sankyo in collaboration with AstraZeneca, Enhertu is widely used in the United States as a next-generation cancer treatment.

FDA-Approved Uses in the United States

In the U.S., Enhertu is approved for:

• HER2-positive breast cancer
• HER2-low breast cancer
• HER2-positive gastric (stomach) cancer
• Non-small cell lung cancer (NSCLC) with HER2 mutations

It is often prescribed for patients who have previously received other treatments.

How Enhertu Works

Enhertu is an antibody-drug conjugate that targets HER2-expressing cancer cells.

It works by:

• Binding to HER2 receptors on cancer cells
• Delivering chemotherapy directly into the tumor
• Destroying cancer cells from within

This targeted approach improves effectiveness while minimizing damage to healthy tissue.

Cost of Enhertu in the USA

Enhertu is one of the most expensive cancer treatments in the United States.

Typical costs include:

• $12,000 – $15,000 per infusion
• $150,000+ per year without insurance

Costs vary based on:

• Insurance coverage
• Treatment schedule
• Infusion center pricing

Because of high costs, many patients look for alternative access options.

Access to Enhertu Without Insurance

Patients in the U.S. who:

• Do not have insurance
• Face high out-of-pocket expenses
• Experience treatment delays

often explore:

• Patient assistance programs
• Alternative sourcing options
• International supply channels

These options may help reduce financial burden.

Benefits of Enhertu Treatment

Enhertu offers several key advantages:

• Highly targeted drug delivery system
• Effective in HER2-low cancers (new treatment option)
• Strong response rates in advanced cancers
• Next-generation therapy beyond traditional HER2 drugs

Possible Side Effects

Common side effects include:

• Nausea
• Fatigue
• Hair loss
• Decreased appetite

Serious side effects may include lung-related complications (interstitial lung disease). Close medical monitoring is required.

Why Patients Look for Alternative Access Options

Due to high U.S. pricing, patients often search for:

• Lower-cost treatment options
• Reliable global suppliers
• Faster medication access

Ensuring authenticity and proper medical supervision is essential.

Conclusion

Enhertu (fam-trastuzumab deruxtecan-nxki) is a breakthrough therapy in the United States for HER2-positive and HER2-low cancers. While highly effective, its high cost leads many patients to explore alternative access solutions.

Understanding your options can help improve access to life-saving treatment.